【PHARMA 7081 交流专区】发马

icy97

印尼业务报喜‧发马次季多赚72%
https://www.sinchew.com.my/content/content_2105406.html

（吉隆坡23日讯）印尼业务向好和受惠于低公司税，促使发马（PHARMA,7081,主板医疗保健组）截至2019年6月30日第二季净利急增72.06%至928万1000令吉。

首半年则受特许经营和非特许经营业务驱动，并受低公司税之惠，净利走高25.75%至2889万8000令吉。

该药商次季营业额受印尼需求高而扬3.29%至6亿零189万令吉，首半年营收增15.60%至13亿8799万8000令吉。

派息2.50仙

发马每股派息2.50仙，9月11日除权、12日享有。

该公司在文告中说，尽管行销与促销成本走高，第二季税前盈利走高4.3%至1200万令吉，首半年税前盈利也走高5%至4300万令吉。

以业务而言，物流和分销业务首半年税前盈利倍增至1900万，这是因为受到非特许业务驱动；特许经营贡献走低，使制造业务则稍微至2800万令吉，惟首半年印尼业务盈利受高营运成本拖累，由120万走低至10万令吉。

展望未来，公司将贯彻策略撷取私人界市场，将加强印尼营运，整体将加强效益以促成持续增长。


文章来源 ： 星洲日报 2019-08-24

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2019	30 Jun 2018	30 Jun 2019	30 Jun 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	601,890	582,729	1,387,998	1,200,652
2	Profit/(loss) before tax	12,481	11,970	42,724	40,677
3	Profit/(loss) for the period	9,262	5,766	28,910	23,355
4	Profit/(loss) attributable to ordinary equity holders of the parent	9,281	5,394	28,898	22,980
5	Basic earnings/(loss) per share (Subunit)	3.56	2.08	11.09	8.84
6	Proposed/Declared dividend per share (Subunit)	2.50	4.00	8.50	9.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.9900		1.9600

icy97

PHARMANIAGA BERHAD

EX-date	11 Sep 2019
Entitlement date	12 Sep 2019
Entitlement time	05:00 PM
Entitlement subject	Second interim dividend
Entitlement description	Second Interim Dividend of 2.5 sen
Period of interest payment	to
Financial Year End	31 Dec 2019
Share transfer book & register of members will be	12 Sep 2019   to   12 Sep 2019 closed from (both dates inclusive) for the purpose of determining the entitlement
Registrar or Service Provider name, address, telephone no	TRICOR INVESTOR & ISSUING HOUSE SERVICES SDN BHDUnit 32-01, Level 32, Tower A,Vertical Business Suite, Avenue 3, Bangsar South,No. 8, Jalan Kerinchi59200Kuala LumpurTel:0327839299Fax:0327839222
Payment date	11 Oct 2019
a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers	12 Sep 2019
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.025

icy97

Type	Announcement
Subject	OTHERS
Description	UPDATE ON THE CONCESSION AGREEMENT DATED 16 MARCH 2011 BETWEEN THE GOVERNMENT OF MALAYSIA (REPRESENTED BY THE MINISTRY OF HEALTH OF MALAYSIA) AND PHARMANIAGA LOGISTICS SDN BHD (Announcement pursuant to Chapter 9 of Bursa Malaysia Securities Berhads Main Market Listing Requirement)
Pharmaniaga Berhad wishes to announce that the period for the Concession Agreement dated 16 March 2011 (“the Concession Agreement”) in relation to purchase, store, supply and distribution of the Approved Products to the Public Sector Customers in accordance with the terms and conditions stipulated therein will expire on 30 November 2019.Pharmaniaga has taken the appropriate action in securing the extension of the Concession Agreement. However, to-date Pharmaniaga has yet to receive any official notification and/or decision from the Ministry of Health.Pending official notification and/or decision from the Ministry of Health, it is business as usual for the Company and we will continue to provide our best services for the rakyat, consistent with our tagline Passion for Patient.Further announcement will be made concerning the Concession Agreement once the Government has made the decision. This announcement is dated 1 November 2019.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=2999195

Attachments Press Release In Response to MOH Statement dated 31 October 2019.pdf

icy97

Type	Announcement
Subject	OTHERS
Description	UPDATE ON THE CONCESSION AGREEMENT DATED 16 MARCH 2011 BETWEEN THE GOVERNMENT OF MALAYSIA (REPRESENTED BY THE MINISTRY OF HEALTH OF MALAYSIA) AND PHARMANIAGA LOGISTICS SDN BHD (Announcement pursuant to Chapter 9 of Bursa Malaysia Securities Berhad Main Market Listing Requirements)
Pharmaniaga Berhad wishes to announce that its wholly owned subsidiary, Pharmaniaga Logistics Sdn Bhd (“PLSB”) has received a letter from the Ministry of Health (“MOH”), extending its services for the provision of medicines and medical supplies to MOH facilities for an interim period of twenty-five (25) months, commencing 1 December 2019 to 31 December 2021. In addition, PLSB secured a five (5) year contract to continue providing logistics and distribution services for MOH for a period of five (5) years ending 31 December 2024. This announcement is dated 18 November 2019.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2019	30 Sep 2018	30 Sep 2019	30 Sep 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	716,849	587,660	2,104,847	1,788,312
2	Profit/(loss) before tax	3,885	17,603	46,609	58,280
3	Profit/(loss) for the period	376	15,305	29,286	38,660
4	Profit/(loss) attributable to ordinary equity holders of the parent	481	15,051	29,379	38,031
5	Basic earnings/(loss) per share (Subunit)	0.18	5.79	11.26	14.63
6	Proposed/Declared dividend per share (Subunit)	0.00	5.00	8.50	14.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.9800		1.9600

icy97

PHARMANIAGA BERHAD

Date of change	31 Mar 2020
Name	DATO' FARSHILA BINTI EMRAN
Age	54
Gender	Female
Nationality	Malaysia
Designation	Managing Director
Directorate	Executive
Type of change	Others
Description	Completion of service contract

Qualifications

No	Qualifications	Major/Field of Study	Institute/University	Additional Information
1	Masters	•        Master of Business Administration	Universiti Utara Malaysia
2	Diploma	Office Management	Universiti Teknologi MARA

Working experience and occupation	Dato Farshila began her career as a tutor in Universiti Teknologi MARA before she became the Assistant Representative of SEVES Sediver France, a French public listed high voltage transmission equipment company in Malaysia, in 1990. Then she was promoted as the Malaysian Representative of the successful company until 2001. Within the same year, she established Idaman Pharma Sdn Bhd and started her venture in the highly regulated pharmaceutical industry.In 2005, she took a bold step by taking over a pharmaceutical plant in Sungai Petani, Kedah and established Idaman Pharma Manufacturing Sdn Bhd (IPMSB). Subsequently, she acquired another plant in Seri Iskandar, Perak. Under her leadership, IPMSB developed a synergistic partnership with Boustead Holdings Berhad (Boustead) and facilitated the acquisition of Pharmaniaga Berhad by Boustead in 2011.Dato Farshila was subsequently appointed as the Managing Director of Pharmaniaga Berhad and since then, she has successfully enhanced the value of the Company.
Family relationship with any director and/or major shareholder of the listed issuer	NIL
Any conflict of interests that he/she has with the listed issuer	NIL
Details of any interest in the securities of the listed issuer or its subsidiaries	458,700 ordinary shares in Pharmaniaga Berhad

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2019	31 Dec 2018	31 Dec 2019	31 Dec 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	715,683	596,644	2,820,530	2,384,956
2	Profit/(loss) before tax	-238,474	11,940	-191,865	70,220
3	Profit/(loss) for the period	-178,733	4,570	-149,447	43,230
4	Profit/(loss) attributable to ordinary equity holders of the parent	-178,598	4,437	-149,219	42,468
5	Basic earnings/(loss) per share (Subunit)	-68.45	1.71	-57.19	16.33
6	Proposed/Declared dividend per share (Subunit)	0.00	2.00	8.50	16.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.2900		1.9600

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2020	31 Mar 2019	31 Mar 2020	31 Mar 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	819,921	786,108	819,921	786,108
2	Profit/(loss) before tax	30,880	30,243	30,880	30,243
3	Profit/(loss) for the period	22,415	19,648	22,415	19,648
4	Profit/(loss) attributable to ordinary equity holders of the parent	22,399	19,617	22,399	19,617
5	Basic earnings/(loss) per share (Subunit)	8.57	7.53	8.57	7.53
6	Proposed/Declared dividend per share (Subunit)	6.00	6.00	6.00	6.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.3400		1.2900

icy97

PHARMANIAGA BERHAD

Entitlement subject	Interim Dividend
Entitlement description	First Interim Dividend of 6 sen
Ex-Date	04 Jun 2020
Entitlement date	05 Jun 2020
Entitlement time	5:00 PM
Financial Year End	31 Dec 2020
Period
Share transfer book & register of members will be	05 Jun 2020 to 05 Jun 2020 closed from (both dates inclusive) for the purpose of determining the entitlement
Payment Date	30 Jun 2020
a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers	05 Jun 2020
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Announced Currency	Malaysian Ringgit (MYR)
Disbursed Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	Malaysian Ringgit (MYR) 0.0600

pts2222

https://www.theedgemarkets.com/a ... res-05-sen-dividend

Tony-Pua

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2020	30 Jun 2019	30 Jun 2020	30 Jun 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	645,763	601,890	1,465,684	1,387,998
2	Profit/(loss) before tax	14,326	12,481	45,206	42,724
3	Profit/(loss) for the period	9,607	9,262	32,022	28,910
4	Profit/(loss) attributable to ordinary equity holders of the parent	9,979	9,281	32,378	28,898
5	Basic earnings/(loss) per share (Subunit)	3.82	3.56	12.39	11.09
6	Proposed/Declared dividend per share (Subunit)	2.50	2.50	8.50	8.50
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.3700		1.2900

PHARMANIAGA BERHAD

Entitlement subject	Interim Dividend
Entitlement description	Second Interim Dividend of 2.5 sen
Ex-Date	07 Sep 2020
Entitlement date	08 Sep 2020
Entitlement time	5:00 PM
Financial Year End	31 Dec 2020
Period
Share transfer book & register of members will be	08 Sep 2020 to 08 Sep 2020 closed from (both dates inclusive) for the purpose of determining the entitlement
Payment Date	06 Oct 2020
a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers	08 Sep 2020
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Announced Currency	Malaysian Ringgit (MYR)
Disbursed Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	Malaysian Ringgit (MYR) 0.0250

icy97

Type	Announcement
Subject	OTHERS
Description	CLARIFICATION ON NEWS ARTICLE  TITLED "PHARMANIAGA PLANTS READY TO TAKE ON COVID VACCINE" APPEARING IN THE STARBIZ DATED 24 AUGUST 2020
As a clarification to the news article titled "Pharmaniaga plants ready to take on Covid Vaccine" appearing in the Starbiz dated 24 August 2020. We wish to inform that with the current need of the nation to speed up production of COVID19 vaccine, Pharmaniaga has offered its existing suitable facility to be repurposed to undertake COVID19 vaccine fill and finish. Presentation on the proposed facility to the MOSTI team led by YB Minister was held in early July and was subsequently presented to Nasional Science Council (NSC) chaired by YAB Prime Minister. Following this, YB MOSTI Minister made announcement that the Government could use the facilities of Pharmaniaga and Duopharma Biotech Berhad for fill and finish of COVID19 vaccine. As at to-date, Pharmaniaga have yet to enter into an agreement with the Government for the project. Pharmaniaga have carried out the necessary study on the changes required and has firmed up the additional CAPEX required to ensure that the plant is ready to undertake the project.

icy97

PHARMANIAGA BERHAD

Date of change	01 Sep 2020
Name	DATUK ZULKARNAIN MD EUSOPE
Age	53
Gender	Male
Nationality	Malaysia
Designation	Managing Director
Directorate	Executive
Type of change	Appointment

Qualifications

No	Qualifications	Major/Field of Study	Institute/University	Additional Information
1	Degree	Engineering	Northern Arizona University

Working experience and occupation

Datuk Zulkarnain brings over 27 years of experience in engineering, corporate planning, fund raising exercise, merger and acquisition. In 1991, he joined Tenaga Nasional Berhad (TNB), the largest Malaysian government owned power company as an Electrical Engineer. He had served in various departments for more than 5 years with TNB. He then joined EPE Power Corporation Berhad, one of the largest public listed engineering company in Malaysia as Project Manager.In 2001, Malaysian Resources Corporation Berhad (MRCB) recruited him as Project Coordinator specializing in engineering related projects. His last assignment saw him leading the International Business Development Unit for the Middle East/South Africa (MESA) and South Asia regions. In 2006, he joined Empire Energy Corp, an international energy company and served as a Senior Vice President with a focus on restructuring distressed power plant projects in South East Asia. He was also tasked to develop coal-fired power plants in Indonesia and led the strategic efforts to acquire the Indonesian company.In 2010, he expanded his horizon and became the Commercial and Corporate Advisor for various companies and provides strategic business development and advisory works to elevate the business to the next level. His vast experiences in developing mega projects locally and internationally has made him profound in many areas. He joined FELCRA Berhad in 2014 as a Chief Investment Officer and was entrusted a bigger role to lead FELCRA Berhad as the Chief Executive Officer in 2016. He was the driving force that took the organization to venture into the property development. Datuk Zulkarnain left FELCRA in October 2018. He currently sits as Board Member at Daya Materials Berhad and Institute of Plantation Management.Datuk Zulkarnain is a well-developed professional with good networks in various government ministries in Malaysia. He is also an Adjunct Professor of Universiti Malaysia Kelantan.

Directorships in public companies and listed issuers (if any)

Daya Materials Berhad

Date of change	01 Sep 2020
Name	ENCIK MOHAMED IQBAL ABDUL RAHMAN
Age	56
Gender	Male
Nationality	Malaysia
Type of change	Others
Designation	Deputy Managing Director
Description	Redesignation

Qualifications

No Qualifications Major/Field of Study Institute/University Additional Information 1 Degree Computer Science Universiti Putra Malaysia
Working experience and occupation	Encik Mohamed Iqbal Abdul Rahman joined Pharmaniaga in 2011 as Director of Information Technology before he was promoted to Chief Operating Officer in 2012. As the Chief Operating Officer, he is responsible for the overall operations of the company. With more than 32 years of experience, mainly in System Improvement & Operations Management, he successfully spearheaded the implementation of Business Intelligence System and Robotic Process Automation, which led to significant improvement to the companys logistics operations. He was also key in the successful implementation of Pharmacy Information System (PHIS) to over 1200 Ministry of Health Malaysia (MOH) facilities throughout Malaysia.  He was appointed as Acting Managing Director on 1 April 2020.Prior to joining Pharmaniaga, Encik Mohamed Iqbal was the General Manager - Head of Operations in Faber Medi-Serve Sdn Bhd (Faber), a provider of hospital support services, reporting directly to the Chief Executive Officer. He was responsible for the companys overall operations and performance, while overseeing all the regional offices, plants and hospitals within the Concession. He was also the key liaison person, leading all the stakeholder engagement activities with MOH.Preceding to his General Manager role, he was the Head of Information and Communication Technology for Faber and Senior Information System Executive for Mayban Assurance Berhad. Early in his career life, he was working as a System Programmer for Maybank Berhad where he was recognized as an outstanding employee.A Bachelor of Computer Science degree holder from University Putra Malaysia, Encik Mohamed Iqbal is a strong believer in the fit-for-purpose technology and cost improvement. His experience and leadership have been focused on developing and delivering technology-driven business solutions, providing outstanding client service, and driving profitable revenue growth.
Family relationship with any director and/or major shareholder of the listed issuer	NIL
Any conflict of interests that he/she has with the listed issuer	NIL
Details of any interest in the securities of the listed issuer or its subsidiaries	NIL

Remarks :

Encik Mohamed Iqbal will relinquish his role as Acting Managing Director and is promoted from Chief Operating Officer to Deputy Managing Director effective 1 September 2020.

icy97

Type	Announcement
Subject	MEMORANDUM OF UNDERSTANDING
Description	Pharmaniaga Berhad ("Pharmaniaga" or "the Company")Memorandum of Understanding between Pharmaniaga Lifescience Sdn Bhd, a wholly-owned subsidiary of the Company and Serum Institute of India Private Limited.
The Board of Directors of Pharmaniaga wishes to announce that Pharmaniaga Lifescience Sdn Bhd, a wholly-owned subsidiary of the Company has on 26 October 2020 entered into a Memorandum of Understanding ('MOU') with Serum Institute of India Private Limited, a company incorporated in India. Please refer to the attachment for details of the announcement. This announcement is dated 26 October 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3099437

Attachments Bursa General Announcement - MOU PLS and SERUM 26.10.2020.pdf

Type	Announcement
Subject	MEMORANDUM OF UNDERSTANDING
Description	Pharmaniaga Berhad ("Pharmaniaga" or "the Company")Memorandum of Understanding between Pharmaniaga Lifescience Sdn Bhd, a wholly-owned subsidiary of the Company and Serum Institute of India Private Limited.
Reference is made to the Company's announcement made on 26 October 2020.      The Company wishes to add that the Memorandum of Understanding ("MOU") shall commence from 26 October 2020 and shall remain in force for a period of twenty-four (24) months, subject to an earlier termination or upon entering into a Definitive Agreement. Before the end of term, both Parties may renew this MOU or enter into a Definitive Agreement. This MOU will expire automatically, unless renewed. Risk factors affecting the MOU include, but not limited to, execution risks such as availability and price fluctuations. Pharmaniaga Group has extensive experience and an established track record in managing and mitigating such risks.      This annoucement is dated 2 November 2020.

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2020	30 Sep 2019	30 Sep 2020	30 Sep 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	624,804	716,849	2,090,488	2,104,847
2	Profit/(loss) before tax	4,093	3,885	49,299	46,609
3	Profit/(loss) for the period	1,294	376	33,316	29,286
4	Profit/(loss) attributable to ordinary equity holders of the parent	1,442	481	33,820	29,379
5	Basic earnings/(loss) per share (Subunit)	0.55	0.18	12.94	11.26
6	Proposed/Declared dividend per share (Subunit)	1.50	0.00	10.00	8.50
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.3200		1.2900

PHARMANIAGA BERHAD

Entitlement subject	Interim Dividend
Entitlement description	Third Interim Dividend of 1.5 sen
Ex-Date	04 Dec 2020
Entitlement date	07 Dec 2020
Entitlement time	5:00 PM
Financial Year End	31 Dec 2020
Period
Share transfer book & register of members will be	07 Dec 2020 to 07 Dec 2020 closed from (both dates inclusive) for the purpose of determining the entitlement
Payment Date	29 Dec 2020
a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers	07 Dec 2020
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Announced Currency	Malaysian Ringgit (MYR)
Disbursed Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	Malaysian Ringgit (MYR) 0.0150

Type	Announcement
Subject	OTHERS
Description	Binding Term Sheet Agreement ("Agreement") between Pharmaniaga Lifescience Sdn Bhd, a wholly-owned subsidiary of Pharmaniaga Berhad and Sinovac Life Sciences Co. Ltd.
The Board of Directors' of Pharmaniaga Berhad ("the Company") wishes to announce that Pharmaniaga Lifescience Sdn Bhd ("PLS"), a wholly-owned subsidiary of the Company has on 12 January 2021 entered into an Agreement with Sinovac Life Sciences Co. Ltd., a subsidiary of the Sinovac Biotech Ltd. for the purchase of ready-to-fill bulk product of Covid-19 vaccine for manufacturing of Covid-19 vaccine by PLS. Please refer to the attachment for details of the announcement. This announcement is dated 12 January 2021.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3120392

Attachments Attachment to the Bursa Malaysia announcement (PLS and Sinovac).pdf

Type	Reply to Query
Reply to Bursa Malaysia's Query Letter - Reference ID	IQL-13012021-00001
Subject	OTHERS
Description	Binding Term Sheet Agreement ("Agreement") between Pharmaniaga Lifescience Sdn Bhd, a wholly-owned subsidiary of Pharmaniaga Berhad and Sinovac Life Sciences Co. Ltd.
Query Letter Contents	We refer to Pharma’s announcement dated 12 January 2021 in respect of the aforesaid matter. In this connection, kindly furnish Bursa Securities with the following additional information for public release: 1) Whether PLS possesses the required expertise, knowhow and resources to manufacture the Covid-19 vaccine. 2) The tentative timeframe to enter into the Local Manufacturing Agreement and a Technology and Know-How License       Agreement with SINOVAC LS. 3) The risks in relation to the manufacturing of the Covid-19 vaccine that PLS may be exposed to. 4) To elaborate the manner in which PLS intends to market and distribute the Covid-19 vaccine and whether any               contract has been secured todate. 5) To specify the relevant authorities’ approvals required for the clinical trial of the Covid-19 vaccine and the                       manufacturing, distribution and sale of the Covid-19 vaccine in Malaysia together with the status of approval,                 where applicable. 6) The estimated total capital outlay or costs to be incurred and the source of funding for the  manufacturing of Covid-      19 vaccine.
Reference is made to Company's announcement on 12 January 2021 and Bursa Malaysia Securities Berhad ("Bursa Securities")'s query letter dated 13 January 2021  pertaining to the above matter. Please refer to the attachment for the full text of the Company's reply to Bursa Securities. This announcement is dated 14 January 2021. Please refer attachment below.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3121091

Attachments Reply Announcement to Bursa Securities Regarding Agreement between PLS and Sinovac.pdf

Type	Announcement
Subject	OTHERS
Description	Term Sheet Agreement (Agreement) between Pharmaniaga Lifescience Sdn Bhd, a wholly-owned subsidiary of Pharmaniaga Berhad, and Government of Malaysia, represented by Ministry of Health, Malaysia.
The Board of Directors of Pharmaniaga Berhad (“the Company”) wishes to announce that Pharmaniaga Lifescience Sdn Bhd, a wholly-owned subsidiary of the Company has on 26 January 2021 entered into an Agreement with Government of Malaysia, represented by Ministry of Health for the purchase and distribution of Covid-19 vaccine, developed by SINOVAC Life Sciences Co. Ltd. Please refer to the attachment for details of the announcement. This announcement is dated 26 January 2021.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3124442

Attachments Attachment to the Bursa Malaysia announcement (PLS and MOH).pdf

icy97

Type	Announcement
Subject	MEMORANDUM OF UNDERSTANDING
Description	Pharmaniaga Berhad ("Pharmaniaga" or "the Company")Memorandum of Understanding between Pharmaniaga Research Centre Sdn Bhd, a wholly-owned subsidiary of the Company and National Institutes of Biotechnology Malaysia.
The Board of Directors of Pharmaniaga wishes to announce that Pharmaniaga Research Centre Sdn Bhd, a wholly-owned subsidiary of the Company has on 1 November 2021 entered into a Memorandum of Understanding (“MOU”) with the National Institutes of Biotechnology Malaysia, to establish a basis of co-operation and collaboration between the parties in relation to vaccines’ research and development. Please refer to the attachment for details of the announcement. This announcement is dated 1 November 2021.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3205796

Attachments Bursa General Announcement - MOU NIBM and PRC 01.11.2021.docx

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2021

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2021	30 Sep 2020	30 Sep 2021	30 Sep 2020
		$$'000	$$'000	$$'000	$$'000

1	Revenue	2,132,675	624,804	4,103,297	2,090,488
2	Profit/(loss) before tax	98,219	4,093	151,987	49,299
3	Profit/(loss) for the period	50,324	1,294	87,040	33,316
4	Profit/(loss) attributable to ordinary equity holders of the parent	49,835	1,442	86,675	33,820
5	Basic earnings/(loss) per share (Subunit)	3.81	0.11	6.62	2.59
6	Proposed/Declared dividend per share (Subunit)	2.00	0.30	4.30	2.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2990		0.2580

icy97

PHARMANIAGA BERHAD

Entitlement subject	Third Interim Dividend
Entitlement description	Third Interim Dividend of 2.0 sen
Ex-Date	06 Dec 2021
Entitlement date	07 Dec 2021
Entitlement time	5:00 PM
Financial Year End	31 Dec 2021
Period
Share transfer book & register of members will be	07 Dec 2021 to 07 Dec 2021 closed from (both dates inclusive) for the purpose of determining the entitlement
Payment Date	29 Dec 2021
a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers	07 Dec 2021
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Announced Currency	Malaysian Ringgit (MYR)
Disbursed Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	Malaysian Ringgit (MYR) 0.0200

Tony-Pua

（吉隆坡14日讯）发马（PHARMA,7081,主板医疗保健组）建议私下配售10％新股筹集4455万令吉还债，分析员认为这只是一个权宜之计，无法令该公司脱离PN17行列，同时预计2023年盈利将被稀释6％。

分析：权宜之计
发马是在昨日建议私下配售最多1亿3102万零866股给第三方投资者。若以每股34仙的参考价计算，预计会筹集到4455万令吉，其中4421万将作为营运资本用途，以付款给供应商／贸易债权人。

肯纳格研究对此企业行动持“中和”看法，认为这只是一个权宜之计，无法让该公司脱离PN17。尽管如此，配股活动筹集的资金将有助融资营运资本，而该公司正在拟定一个整体解决方案来脱离PN17。

以每股34仙的参考价计算，该公司料筹集到4455万令吉资金，可将净负债从2023年3月31日的11亿9000万令吉略为改善至11亿5000万令吉，而2023年每股盈利料稀释6％。

前景谨慎
该行审慎看待发马的前景，因为该公司截至3月杪的股东权益为负1亿4300万令吉，将影响派息能力及政府寻求更物有所值的合约，该公司可能需要降低收费。

丰隆研究则表示，私下配售之后，发马的股东权益将从3月杪的负1亿4280万令吉稍微改善至负9820万令吉，仍然处于负值区域。

在私下配售和雇员认购全面行使后，该公司的每股盈利将稀释约11％，到时目标价将从30仙下调至26仙。

虽然私下配售将带来稀释效应，但丰隆仍然对此进展持正面看法，因为这比银行贷款更可行。如果向银行借贷，利息成本将升高，从而影响盈利。

不过，该行仍然保持“沽售”评级，因为此私下配售行动不足以让该公司脱离PN17，股东权益保持在负值区域。

发马今日闭市股价报37仙，全日微跌1仙。

icy97

PHARMANIAGA BERHAD

Date of change	08 Mar 2024
Name	ENCIK MOHAMED IQBAL ABDUL RAHMAN
Age	60
Gender	Male
Nationality	Malaysia
Type of change	Retirement
Designation	Chief Operating Officer

Qualifications

No Qualifications Major/Field of Study Institute/University Additional Information 1 Degree Bachelor in Computer Science Universiti Putra Malaysia
Working experience and occupation	Encik Mohamed Iqbal joined Pharmaniaga in 2011 as Director of Information Technology before promoted to Chief Operating Officer in 2012. With more than 32 years of experience, mainly in System Improvement & Operations Management, he spearheaded the implementation of the Business Intelligence System and Robotic Process Automation, and played a vital role in the implementation of the Pharmacy Information System ("PhIS") to over 1,200 Ministry of Health ("MOH") facilities.On 1 April 2020, he was appointed as Acting Managing Director and subsequently appointed as Deputy Managing Director on 1 September in the same year. He was also serving as Commissioner of PT. Millennium Pharmacon International Tbk. ("MPI") between 2012 to 2021. During the pandemic, Encik Mohamed Iqbal was responsible for leading a team to successfully implement fill and finish manufacturing of theSinovac Covid-19 vaccine. In 2023, Encik Mohamed Iqbal led a team to a successful negotiation of the new concession agreement with MOH.Prior to joining Pharmaniaga, Encik Mohamed Iqbal was the General Manager - Head of Operations in Faber Medi-Serve Sdn Bhd, a provider of hospital support services. He was responsible for the companys overall operations whilst overseeing all the regional offices, plants and hospitals within the Concession. He was also the key liaison person, leading all the stakeholder engagement activities with MOH.A Bachelor of Computer Science degree holder from University Putra Malaysia, Encik Mohamed Iqbal is a strong believer in fit for purpose technology and cost improvement. His experience and leadership have been focused on developing and delivering technology-driven business solutions, providing outstanding client service, and driving profitable revenue growth.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2024

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2024	30 Jun 2023	30 Jun 2024	30 Jun 2023
		$$'000	$$'000	$$'000	$$'000

1	Revenue	838,256	848,734	1,803,215	1,729,188
2	Profit/(loss) before tax	3,334	6,342	42,378	15,535
3	Profit/(loss) for the period	3,846	2,324	30,025	5,090
4	Profit/(loss) attributable to ordinary equity holders of the parent	2,797	1,961	28,443	4,608
5	Basic earnings/(loss) per share (Subunit)	0.19	0.15	1.97	0.35
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	-0.1894		-0.2075